Notably, both of these studies reported heterogeneity in T‐cell activation in COVID‐19 patients and provided evidence that both CD4+ and CD8+ T cells are capable of mounting potent immune responses with potential emergence of impaired or excessive T‐cell responses. The gene discussed is CD4; the disease is COVID-19.